CareStart™ COVID-19 Rapid IgM/IgG Antibody Test
The CareStart™ COVID-19 IgM/IgG Rapid Antibody Test for the Detection of SARS-CoV-2 IgM/IgG Ab provides a fast and simple diagnostic tool in a qualified Clinical Laboratory Improvement Amendments (CLIA) setting for identification and monitoring of an individual’s previous infection history and immune response to COVID-19.
This antibody test manufactured by Access Bio is CE Certified and has been authorized by the FDA under an Emergency Use Authorization (EUA). For nearly 20 years, Access Bio has been a global leader in engineering and manufacturing superior-quality diagnostic testing for infectious diseases.
Product Features
- Fast and easy to use in a qualified CLIA setting
- Detect and differentiate IgM/IgG antibody specific to SARS-CoV-2
- Requires small sample volume (10 uL of whole blood, serum, or plasma)
- Results available in 10 minutes
- No special equipment or training required
- Identify and monitor individual’s previous infection history and immune response to COVID-19
- Clinical performance (NIH/NCI) of 100% sensitivity and 97.5% specificity
- Manufactured in the USA